Regencell Bioscience (RGC) director discloses 604,050 shares and major option grant

Rhea-AI Filing Summary

Regencell Bioscience Holdings Ltd director Margaret Hoor Han Lo has filed an initial ownership report showing her equity position in the company. She directly holds 604,050 ordinary shares. She also holds a stock option to purchase 592,230 ordinary shares at an exercise price of $17.40 per share, expiring on June 29, 2035. According to the disclosure, this option was granted on June 30, 2025 under the company’s 2021 Share Option Plan and vests in four equal annual installments on each anniversary of the grant date. The filing does not record any new purchases or sales, only the existing holdings and option grant terms.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

LO MARGARET HOOR HAN

(Last) (First) (Middle)

C/O 9/F CHINACHEM LEIGHTON PLAZA

29 LEIGHTON ROAD, CAUSEWAY BAY

(Street)

HONG KONG

(City) (State) (Zip)

CHINA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Regencell Bioscience Holdings Ltd [ RGC ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary shares, par value $0.00001	604,050	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to purchase)	(1)	06/29/2035	Ordinary shares, par value $0.00001	592,230	$17.4	D

Explanation of Responses:

1. The Reporting Person was granted the option on June 30, 2025 pursuant to the Issuer's 2021 Share Option Plan. The option will vest equally upon each of the four anniversaries of the grant date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ James Wai Hong Chung, attorney-in-fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What insider holdings did Regencell Bioscience (RGC) report for Margaret Hoor Han Lo?

Margaret Hoor Han Lo reported direct ownership of 604,050 ordinary shares of Regencell Bioscience. The filing is an initial ownership statement, showing her existing position rather than new transactions, helping investors understand her direct equity stake in the company.

What stock options does Margaret Hoor Han Lo hold in Regencell Bioscience (RGC)?

She holds a stock option to purchase 592,230 ordinary shares at an exercise price of $17.40 per share. The option expires on June 29, 2035, providing long-term potential equity exposure if fully vested and exercised over time.

How do Margaret Hoor Han Lo’s options in RGC vest over time?

The option granted on June 30, 2025 vests in four equal installments. It vests on each of the four anniversaries of the grant date, meaning 25% of the total underlying shares become exercisable each year, aligning her incentives with multi‑year company performance.

Does the Regencell Bioscience (RGC) Form 3 show any insider buying or selling?

The Form 3 does not show any insider buying or selling activity. It only reports existing holdings: direct ownership of ordinary shares and an outstanding stock option grant, serving as a baseline ownership snapshot as she serves as a director.

What is the significance of this Form 3 filing for Regencell Bioscience (RGC)?

The Form 3 establishes a baseline record of Margaret Hoor Han Lo’s holdings as a company director. It discloses her direct share ownership and option grant terms, improving transparency about management’s equity interests for investors evaluating insider alignment.